Lonza’s Synaffix Collaborates with BigHat Biosciences on the Development of a Machine Learning-Designed ADC
- Commercial license to Synaffix technologies follows a series of successful initial preclinical proof of concept studies
- Collaboration underscores Lonza’s commitment to helping customers deliver innovative new therapies to patients by offering a comprehensive service offering for differentiated ADCs
- BigHat’s artificial intelligence (AI)/machine learning (ML)-powered antibody design platform, Milliner™ was used to design a highly differentiated antibody that was paired with Synaffix’s GlycoConnect™, HydraSpace® and toxSYN® ADC technologies to generate a next-gen ADC
Amsterdam, The Netherlands, and Basel, Switzerland, 4 November 2024 — Synaffix B.V. (“Synaffix”), a Lonza company (SWX:LONN) focused on commercializing its clinical-stage platform technology for the development of antibody-drug conjugates (ADCs) with best-in-class therapeutic index, today announced that it has licensed its ADC technology to BigHat Biosciences, Inc. (“BigHat”). BigHat will combine Synaffix technology with its world-class ML antibody design platform for the development of a new ADC pipeline program.
